• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BioVersys Gets EIB Funds to Address Antimicrobial Resistance

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    BioVersys Gets EIB Funds to Address Antimicrobial Resistance

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Reed-Lane

    Emergent BioSolutions

    Alcami

    Quotient Sciences
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Aphena Pharma Solutions

    Syngene

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers: LSNE

    LSNE Expands Capabilities and QC Laboratory Space

    Newsmakers: LSNE
    Related CONTENT
    • Alcami
    • Altasciences
    • Vetio Animal Health
    • Interphex Exhibitor List
    • Back to the (BIO)Future!
    Tim Wright, Editor05.08.18
    Lyophilization Services of New England (LSNE), a contract development and manufacturing organization (CDMO), recently unveiled a strategic plan to expand its quality control (QC) laboratory in Bedford, NH. The build-out calls for 37,000 square feet of new QC laboratory space and a centralized warehouse. Additionally, in conjunction with this expansion, LSNE will add approximately 45 new full-time positions. 

    The new, state-of-the-art laboratory will allow LSNE to increase its analytical and microbiology capabilities, to continue to support clients with their clinical and commercial products.
    The laboratory building, located on LSNE’s campus, will also house LSNE’S newly renovated centralized warehouse to support the company’s continued growth, including the offering of longer-term product storage for clients. The laboratory and warehouse are scheduled to be validated and operational during the second quarter of 2018. Recently, Contract Pharma had a chance to sit down with Jeff Clement, Director of Sales at LSNE and talk about the new lab.


    Contract Pharma: Why was the decision made to expand LSNE’s lab space?

    Jeff Clement:
    We listened to our clients. It’s been our company philosophy since the beginning. LSNE started out as a development and manufacturing company for lyophilized products. Then, as we grew, we got more and more into manufacturing, starting off with building our medical devices and diagnostics client base. Then we made the natural progression into sterile drug product manufacturing.

    Recently we’ve heard from a lot of our clients that have long lead times with some of their 3rd party quality control (QC) testing labs. We’ve always had a QC lab, but we thought it would be an opportune time to further support our clients and increase our analytical capabilities. Our laboratory is expanding in both personnel and equipment, while the actual size of it will grow about four-fold.

    The whole build out is comprised of QC lab space and a consolidated warehouse with large capacity for controlled storage requirements. We currently have four manufacturing sites.
    Each one of them has their own warehouse space. Part of the plan with this new 38,000 sq. ft. of space is to have that as a consolidated warehouse. Now each of the individual manufacturing sites have more of a ‘just-in-time’ warehouse. This allows us to be more nimble and responsive to the client’s schedules. Additionally, we now have more manufacturing supplies available to support our clients.

    CP: How does the new space help address customer needs?

    JC:
    All of our clients will have either testing to get their Active Pharmaceutical Ingredient (API) or the Bulk Drug Substance (BDS) released, as well as any in-process control testing, release testing and/or stability testing. Some of the bottlenecks we’ve seen occur is when our clients do not have a method assay established yet. That will slow down the process if they’re outsourcing that method to a third party laboratory and we’ve heard from our clients that the lead times on testing are getting longer and longer. Our QC team will be available for clients to develop assays or take an existing assay from the upstream manufacturer and further develop that or optimize it depending on the stage of the product.

    CP: How does the expansion complement other business capabilities and fold into other areas of expertise?

    JC:
    It’s really two-fold. The first part revolves around working with our existing client base. We’ve upgraded the instrumentation we have for high performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) testing and have increased personnel for a lot of standard physical chemistries like osmolality and pH testing. In fact, we recently have moved our QC function to a 7 Day, two shift operation. I also mentioned the scientists we’ve brought onboard to perform method development and we’re also getting into more complex process formulation and filling. A lot of these capabilities require specialized equipment. Recently we’ve added on gas chromatography (GC) equipment. We’re also in the process of getting GC upgraded so we can test the head space analysis on residual solvents. Recently we even added a headspace analyzer to determine oxygen content in the vials.
    In addition, we’ve had a number of clients developing nanoparticles or micro-sphere products. In response to this trend we offer a dedicated ISO-5 formulation suite. We also added a particle sizer and zeta potential testing to our capabilities in supporting this emerging area.

    So these are some of the things we’ve added on to further support our traditional existing clients. The additional equipment will help to support our newer types of complex processes.
    The second part of LSNE’s recent growth has to do with expanding into the existing analytical market. Traditionally, we’ve only supported the projects that we’re manufacturing. But right now we’re expanding our testing services for different dosage forms. Historically, LSNE has only worked with injectable drug products, but now we’re actually getting into stand-alone testing where we can test for not only APIs or intermediates, but we can also test for oral products, topicals, and other various routes of administration.

    Overall, LSNE is going through a broad expansion much beyond our traditional niche.

    CP: What have been some of the challenges encountered during this expansion process?

    JC:
    I think with the QC space the biggest challenge that we’ll have, especially where we’re outside of the parenteral marketplace, is dealing with the fact that we may not be well known in the oral dosage form and topicals market. We can perform that testing but I don’t think anybody would really be looking for us to do it. We’re going to have to get out into the market and let people know that we’re now offering these standalone testing capabilities. Especially where some companies might have a pain point of long lead times, now we’re willing to take on new business, where traditionally it’s only been a supporting arm of our business.

    We’ll be undergoing branding and marketing initiatives while training sales staff to sell the analytical services we now offer. Ultimately, it’s about letting our existing customers, as well as potential new customers, know that we can provide more now than just a manufacturing supporting role in the analytical services area.

    CP: What are some of trends in general driving the analytical and microbiological testing market?

    JC:
    I think a lot of the drive right now has to do with the through-put of business in general. A lot of the well-known analytical testing labs are overbooked so it presents an opportunity for a company like ours that does have excess QC capacity to expand our horizons a little bit and move further into the analytical testing space.

    CP: In addition to the new lab space and warehouse, are there any other expansion plans?

    JC:
    We are now working with our existing commercial clients to perform the labelling and meet all the new serialization requirements for them. In addition, we’ll also offer these capabilities as a stand-alone service. I think we’re a little bit ahead of the curve, by getting our commercial clients all set with the outside vendor, which has in-turn provided us with a lot of experience in this area. Now we’re taking that experience and working with a vendor to perform those services at LSNE. There’s potential for us to be doing labelling for a lot of our competitors which will be a great opportunity for us.

    Additionally, LSNE recently acquired PSC Biotech’s cGMP aseptic fill finish manufacturing facility located in Madison, WI. This acquisition allows LSNE to expand its manufacturing capabilities, add new service offerings and accommodate its customers’ project timing requirements. The new facility will be called LSNE-Madison.

    CP: What are some other areas LSNE will look to grow its business moving forward?

    JC:
    While we will always maintain our core manufacturing in supporting our clients, we’ll also continue to expand our horizons such as with the expanded QC capabilities and the serialization initiative. A couple other markets that we’re looking at now for potential growth is in the area of gene therapy and microbiome products. There is a lot of recent interest in these areas.

    Our company philosophy is we look to buy our own buildings so we can react quickly and respond to market demands. Right now we have a couple buildings we’re planning further expansion into on our Bedford, NH campus. One of these areas will focus on gene therapy and microbiome products. For now we’re calling it “flex-space” where we will start with some development of these microbiome live cell products that is completely outside our standard GMP manufacturing process in completely separate facilities. Our first projects will be non-GMP R&D work. But what we have going for us is 21 years of lyophilization experience that will help us develop lyophilization cycles for the client. One of our sites has a lot of bulk lyophilization capabilities, and while this work would not be performed at that site, the experience we have in bulk lyophilization is readily transferable with the microbiome products.

    This is one other way we’re getting our name out there to see how the market is looking at us. We’ll see how it goes and ultimately decide if we want to make that leap in investment into getting some GMP manufacturing for microbiome and gene therapy products, in the near future. 
    Related Searches
    • quality
    • serialization
    • Filling
    • Stability Testing
    Suggested For You
    Alcami Alcami
    Altasciences Altasciences
    Vetio Animal Health Vetio Animal Health
    Interphex Exhibitor List Interphex Exhibitor List
    Back to the (BIO)Future! Back to the (BIO)Future!
    Rising CMO Business Fortunes Rising CMO Business Fortunes
    The Beginning of a New Era? The Beginning of a New Era?
    LSNE Acquires PSC Biotech’s Parenteral Mfg. Facility LSNE Acquires PSC Biotech’s Parenteral Mfg. Facility
    Avema to Showcase Range of Services Avema to Showcase Range of Services
    Contract Pharma Welcomes New Associate Editor Contract Pharma Welcomes New Associate Editor
    LSNE Expands Capabilities and QC Laboratory Space LSNE Expands Capabilities and QC Laboratory Space
    Idifarma Expands High Potent Capabilities Idifarma Expands High Potent Capabilities
    Integrated Early-Stage Drug Development and Manufacturing Integrated Early-Stage Drug Development and Manufacturing
    FDCs on the Rise FDCs on the Rise
    The Logistics Behind Personalized Medicine Delivery The Logistics Behind Personalized Medicine Delivery

    Related Features

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Analytical Services | Laboratory Testing
      The Time Has Come

      The Time Has Come

      Looking at the change from USP <231> to USP <232> and <233> and what it means.
      Nikki Schopp, Assistant Manager, Analytical Laboratory Services at SGS Life Sciences 04.10.18


    • Analytical Services
      Getting from Risk Assessment to Regulatory Submission

      Getting from Risk Assessment to Regulatory Submission

      Taking the next steps from risk assessment through method development, method validation and testing to the updating of an an
      Anthony DeStefano and Thomas Kester, Recordati Rare Diseases, Inc. 03.09.18

    • Analytical Services | Methods Development
      Analytical Method Transfer  Best Practices

      Analytical Method Transfer Best Practices

      Avoiding the perils of analytical method transfer
      Wayland Rushing, Director, Scientific Affairs, EAG Laboratories 11.07.17

    • Analytical Services | Bioanalytical Services | R&D
      CROs & Next-Gen  Drug Development

      CROs & Next-Gen Drug Development

      R&D trends drive outsourcing in today’s market
      Kristin Brooks, Contract Pharma 05.09.17


    • Analytical Services | Laboratory Testing
      Analytical Testing Outsourcing Trends Update

      Analytical Testing Outsourcing Trends Update

      Spurred by many factors, global analytical testing services market is experiencing rapid growth in the range of 11% per year
      01.26.17

    • Analytical Services | Drug Development | Drug Discovery | Preclinical Outsourcing | R&D
      The Human Parts of Mouse Models

      The Human Parts of Mouse Models

      The PDX model system has come back into focus
      Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company 10.11.16

    • Analytical Services | Bioassay Development | Clinical Trials | Preclinical Outsourcing | R&D
      Robust Assay Designs

      Robust Assay Designs

      Easing the transition from preclinical to clinical research
      Tim Wright, Editor, Contract Pharma 10.11.16


    • Analytical Services | Drug Development | Laboratory Testing
      Elemental Impurity Testing

      Elemental Impurity Testing

      Advances in elemental impurity testing aid compliance with new USP requirements
      Dr. Andrew Fussell, PANalytical 01.28.16

    • Analytical Services | Biosimilars | Clinical Trials | Drug Development | Formulation Development

      Why True CDMO Service Requires Flexibility, Responsiveness and Innovation

      Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
      James E. Gregory, UPM Pharmaceuticals 10.07.15

    • Analytical Services | Biosimilars | Clinical Trials | Cold Chain Management | Drug Development | Logistics | R&D | Supply Chain
      CRO Outlook & Drug Development Trends

      CRO Outlook & Drug Development Trends

      CRO industry grows as increasingly complex R&D trends demand advanced expertise
      Kristin Brooks , Contract Pharma 05.06.15


    • Analytical Services | Process Development | Supply Chain
      Changing Prices in the Bio CMO Market

      Changing Prices in the Bio CMO Market

      A dynamic market for biopharmaceutical contract manufacturing services is seeing prices rise and fall
      William Downey , President, HighTech Business Decisions 03.06.15

    • Analytical Services | APIs | Aseptic Processing | Bioanalytical Services | Bioassay Development | Capsules | Chemistry | Cleaning Validation | Clinical Trials | Drug Development | Drug Discovery | Excipients | Extractables and Leachables | Facilities | Fill/Finish | Formulation Development | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Process Development | Serialization | Supply Chain | Toxicology | Validation
      Contract Pharma’s 15th Anniversary Retrospective: Then & Now

      Contract Pharma’s 15th Anniversary Retrospective: Then & Now

      A look back at the pharma/biopharma industry and outsourcing.
      Kristin Brooks, Contract Pharma 10.14.14

    • Analytical Services | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Drug Development | Regulatory Affairs | Toxicology | Validation
      Improving the Functional Characterization of Biosimilars

      Improving the Functional Characterization of Biosimilars

      New bioassay methods may help reduce the variability of analytical methods required to demonstrate comparability
      Delana Butz, Ph.D., Manuela Grassi, Ph.D, Onesmo Mpanju, Ph.D., Duu-Gong Wu, Ph.D., Peter Wunderli, Ph.D. , PPD 06.03.14

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Executive Moves: Novavax
    • Ensuring Pharma Manufacturing Quality
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA “Letter of No Objection” on GRAS Status
    6th Annual Dietary Supplements Regulatory Summit Scheduled for July 13
    Bunge Invests $47.5 Million in Australian Plant Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    VideoBite: Engineered Polymer Solutions
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Medtronic Introduces Extended Infusion Set in Europe
    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    Hallstar Beauty Names New President
    The Fragrance Foundation Announces the 2021 Awards Finalists
    Azelis Earns 'Coup de Coeur' Award at Cosmetagora 2021
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson SurePress reaches milestone
    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PCMC Redesigns Rx200 and Mako Clipper Wet Wipes Machines
    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login